Transnasal Sphenopalatine Ganglion Block for Treatment of Acute Subarachnoid Hemorrhage Associated Headache

Part of paid clinical trials in Sacramento, California.

Sponsor
University of California, Davis
Study ID
NCT06621329
Phase
PHASE2/PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Headache
  • SAH (Subarachnoid Hemorrhage)

Eligibility Criteria

Sex
ALL
Age
18 Years - 100 Years
Healthy Volunteers
Not accepted

Interventions

  • Transnasal sphenopalatine ganglion block — COMBINATION_PRODUCT
    Transnasal sphenopalatine ganglion blocks will be performed using the Tx360 device. Medications used during the procedure include 0.75% bupivacaine with or without 1 mg of preservative free dexamethasone.

Study Details

The study titled \"Transnasal sphenopalatine ganglion block for treatment of acute subarachnoid hemorrhage associated headache\" is a randomized controlled pilot study aimed at evaluating the efficacy of a transnasal sphenopalatine ganglion (SPG) block in addition to standard pain medication for reducing headache severity in patients with acute subarachnoid hemorrhage (aSAH). The study also examines whether this intervention can reduce opioid requirements during hospitalization and upon discharge.

Key Dates

Start date
Oct 17, 2024
Status verified
Nov 2025
Primary completion
Jul 31, 2026
Completion
Oct 31, 2026

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • No Intervention: Standard of Care Medications for Headache
    Control arm participants will receive standard of care medications, as defined in a headache protocol, to treat subarachnoid associated headache.
  • Experimental: Transnasal SPG Block and Standard of Care Medications
    Intervention arm participants will receive standard of care medications, as defined in a headache protocol, with the addition of transnasal SPG blocks when a predefined threshold is met per the study protocol.

Primary Outcome Measure

Numerical pain rating scale [ Time Frame: From enrollment until ICU discharge, up to 14 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UC Davis Medical CenterSacramentoCalifornia95817
Christine Picinich, AGACNP-BC, MS
[email protected]
7075368452
Christine Picinich
Christine Picinich, AGACNP-BC, MS (PRINCIPAL_INVESTIGATOR)

Find similar trials in Sacramento, CA

By research site
UC Davis Medical Center· Sacramento, CA

Related Studies